Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cutivate
2. Flixonase
3. Flixotide
4. Flonase
5. Flovent
6. Flovent Hfa
7. Fluticasone
8. Hfa, Flovent
9. Propionate, Fluticasone
1. 80474-14-2
2. Flovent
3. Cutivate
4. Flixotide
5. Flonase
6. Flixonase
7. Flovent Hfa
8. Flunase
9. Flusonal
10. Fluspiral
11. Flutide
12. Flutivate
13. Asmatil
14. Axotide
15. Brethal
16. Fluinol
17. Flovent Diskus 50
18. Flixotide Disks
19. Flixotide Disk
20. Flovent Diskus
21. Flovent Diskus 100
22. Flovent Diskus 250
23. Flixotide Inhaler
24. Cultivate
25. Flixonase Nasal Spray
26. Fluticasonpropionat Allen
27. Cci-18781
28. Xhance
29. Fluticasone (propionate)
30. Cci 18781
31. Armonair Respiclick
32. Fluticasone-17-propionate
33. O2gmz0lf5w
34. Atemur
35. Chebi:31441
36. Nsc-759889
37. Inalacor
38. Rinosone
39. Trialona
40. Ubizol
41. Zoflut
42. Fluticasone Propionate (flonase, Veramyst)
43. Mfcd00866007
44. Flonase Aq
45. Pf-00241939
46. [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Propanoate
47. Flovent-hfa
48. Fluticasone Propionate [usan]
49. Unii-o2gmz0lf5w
50. Fluxonal
51. Skyron
52. Flovent Rotadisk
53. Cutivate (tn)
54. Fluticasone Propionate [usan:usp]
55. Flonase (tn)
56. Flovent (tn)
57. Fluticasone-propionate
58. Armonair Respiclicktm
59. Flonase Allergy Relief
60. Fluticasone Impurity B
61. Prestwick0_000997
62. Prestwick1_000997
63. Prestwick2_000997
64. Prestwick3_000997
65. Cci18781
66. Schembl4068
67. Chembl1473
68. Bspbio_001093
69. Mls001424085
70. S-(fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate
71. Fluticasone Propionate- Bio-x
72. Spbio_002984
73. Bpbio1_001203
74. Gtpl7080
75. Dtxsid8045511
76. Fluticasone Propionate (jan/usp)
77. Fn-25
78. Hms1571g15
79. Hms2051n19
80. Hms2098g15
81. Hms3413a19
82. Hms3677a19
83. Hms3715g15
84. Fluticasone Propionate [mi]
85. Amy38235
86. Hy-b0154
87. Ymb56612
88. Zinc3920027
89. Fluticasone Propionate [jan]
90. Ac-457
91. Bdbm50354849
92. S1992
93. Fluticasone Propionate [vandf]
94. Akos015895220
95. Fluticasone Propionate [mart.]
96. Ccg-100981
97. Cci-187881
98. Cs-1986
99. Db00588
100. Fluticasone Propionate [usp-rs]
101. Fluticasone Propionate [who-dd]
102. Ks-1173
103. Nc00231
104. Nsc 759889
105. Ncgc00179308-01
106. Ncgc00179308-05
107. Androsta-1,4-diene-17-carbothioic Acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-s-(fluoromethyl) Ester
108. Bf160362
109. Bf161262
110. Smr000469159
111. Fluticasone Propionate [orange Book]
112. Ab00513992
113. Fluticasone Propionate [ep Monograph]
114. Advair Component Fluticasone Propionate
115. Fluticasone Propionate [usp Monograph]
116. A51110
117. D01708
118. Dymista Component Fluticasone Propionate
119. Ab00513992-06
120. Ab00513992_08
121. Fluticasone Propionate - Micronised Pharma Grade
122. Fluticasone Propionate Component Of Advair
123. Fluticasone Propionate, >=98% (hplc), Powder
124. 474f142
125. Advair Hfa Component Fluticasone Propionate
126. An-584/43505443
127. Fluticasone Propionate 100 Microg/ml In Methanol
128. Fluticasone Propionate Component Of Dymista
129. Lipo-102 Component Fluticasone Propionate
130. Sr-01000763355
131. Q-101393
132. Q8564098
133. Sr-01000763355-3
134. Brd-k62310379-001-03-0
135. Fluticasone Propionate 100 Microg/ml In Acetonitrile
136. Fluticasone Propionate Component Of Advair Hfa
137. Airduo Respiclick Component Fluticasone Propionate
138. Fluticasone 17(2)-carbonylsulfenic Acid 17-propionate
139. Fluticasone Propionate Component Of Airduo Respiclick
140. Fluticasone Propionate, European Pharmacopoeia (ep) Reference Standard
141. Fluticasone Propionate, United States Pharmacopeia (usp) Reference Standard
142. Fluticasone Propionate, Pharmaceutical Secondary Standard; Certified Reference Material
143. (1r,2s,8s,10s,11s,13r,14r,15s,17s)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl Propanoate
144. (6?,11?,16?,17?)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic Acid Fluoromethyl Ester
145. 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl Propanoate
146. Androsta-1,4-diene-17-carbothioic Acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)-s-(fluoromethyl) Ester
147. Androsta-1,4-diene-17-carbothioic Acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-,s-(fluoromethyl) Ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)-
148. Fluticasone Propionate For Impurity C Identification, Europepharmacopoeia (ep) Reference Standard
149. Fluticasone Propionate For Impurity G Identification, Europepharmacopoeia (ep) Reference Standard
150. S-fluoromethyl 6.alpha., 9.alpha.-difluoro-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-17.alpha.-propionyloxyandrosta-1,4-diene-17.beta-. Carbothioate
| Molecular Weight | 500.6 g/mol |
|---|---|
| Molecular Formula | C25H31F3O5S |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | 500.18442974 g/mol |
| Monoisotopic Mass | 500.18442974 g/mol |
| Topological Polar Surface Area | 106 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 984 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 14 | |
|---|---|
| Drug Name | Cutivate |
| PubMed Health | Fluticasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Intermediate, Corticosteroid, Strong |
| Drug Label | CUTIVATE (fluticasone propionate cream) Cream, 0.05% contains fluticasone propionate [(6,11,16,17)-6,9,-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester], a synthetic fluorina... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Lotion; Ointment |
| Route | Topical |
| Strength | 0.05%; 0.005% |
| Market Status | Prescription |
| Company | Fougera Pharms |
| 2 of 14 | |
|---|---|
| Drug Name | Flonase |
| Drug Label | The active component of FLOVENT HFA 44 mcg Inhalation Aerosol, FLOVENT HFA 110 mcg Inhalation Aerosol, and FLOVENT HFA 220 mcg Inhalation Aerosol is fluticasone propionate, a corticosteroid having the chemical name S-(fluoromethyl) 6,9-difluoro-11... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | 0.05mg/spray |
| Market Status | Prescription |
| Company | Glaxosmithkline |
| 3 of 14 | |
|---|---|
| Drug Name | Flovent diskus 100 |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Powder |
| Route | Inhalation |
| Strength | 0.1mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
| 4 of 14 | |
|---|---|
| Drug Name | Flovent diskus 250 |
| Drug Label | Fluticasone propionate, the active component of Fluticasone Propionate Nasal Spray USP, is a synthetic corticosteroid having the chemical name S-(fluoromethyl)6,9-difluoro-11-17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate, 17-... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Powder |
| Route | Inhalation |
| Strength | 0.25mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
| 5 of 14 | |
|---|---|
| Drug Name | Flovent diskus 50 |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Powder |
| Route | Inhalation |
| Strength | 0.05mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
| 6 of 14 | |
|---|---|
| Drug Name | Flovent hfa |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Aerosol, metered |
| Route | Inhalation |
| Strength | 0.22mg/inh; 0.11mg/inh; 0.044mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
| 7 of 14 | |
|---|---|
| Drug Name | Fluticasone propionate |
| Drug Label | Fluticasone propionate, the active component of FLONASE Nasal Spray, is a synthetic corticosteroid having the chemical name S-(fluoromethyl)6,9-difluoro-11-17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate, 17-propionate and the... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Ointment; Spray, metered; Cream; Lotion |
| Route | Nasal; Topical |
| Strength | 0.05%; 0.005%; 0.05mg/spray |
| Market Status | Prescription |
| Company | Wockhardt; Apotex; Roxane; Glenmark Generics; Fougera Pharms; Hi Tech Pharma; Perrigo New York; Tolmar; G And W Labs; Perrigo Israel |
| 8 of 14 | |
|---|---|
| Drug Name | Flovent diskus 250 |
| Drug Label | Fluticasone propionate, the active component of Fluticasone Propionate Nasal Spray USP, is a synthetic corticosteroid having the chemical name S-(fluoromethyl)6,9-difluoro-11-17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate, 17-... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Powder |
| Route | Inhalation |
| Strength | 0.25mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
| 9 of 14 | |
|---|---|
| Drug Name | Flovent diskus 50 |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Powder |
| Route | Inhalation |
| Strength | 0.05mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
| 10 of 14 | |
|---|---|
| Drug Name | Flovent hfa |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Aerosol, metered |
| Route | Inhalation |
| Strength | 0.22mg/inh; 0.11mg/inh; 0.044mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
| 11 of 14 | |
|---|---|
| Drug Name | Fluticasone propionate |
| Drug Label | Fluticasone propionate, the active component of FLONASE Nasal Spray, is a synthetic corticosteroid having the chemical name S-(fluoromethyl)6,9-difluoro-11-17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate, 17-propionate and the... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Ointment; Spray, metered; Cream; Lotion |
| Route | Nasal; Topical |
| Strength | 0.05%; 0.005%; 0.05mg/spray |
| Market Status | Prescription |
| Company | Wockhardt; Apotex; Roxane; Glenmark Generics; Fougera Pharms; Hi Tech Pharma; Perrigo New York; Tolmar; G And W Labs; Perrigo Israel |
| 12 of 14 | |
|---|---|
| Drug Name | Cutivate |
| PubMed Health | Fluticasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Intermediate, Corticosteroid, Strong |
| Drug Label | CUTIVATE (fluticasone propionate cream) Cream, 0.05% contains fluticasone propionate [(6,11,16,17)-6,9,-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester], a synthetic fluorina... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Lotion; Ointment |
| Route | Topical |
| Strength | 0.05%; 0.005% |
| Market Status | Prescription |
| Company | Fougera Pharms |
| 13 of 14 | |
|---|---|
| Drug Name | Flonase |
| Drug Label | The active component of FLOVENT HFA 44 mcg Inhalation Aerosol, FLOVENT HFA 110 mcg Inhalation Aerosol, and FLOVENT HFA 220 mcg Inhalation Aerosol is fluticasone propionate, a corticosteroid having the chemical name S-(fluoromethyl) 6,9-difluoro-11... |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | 0.05mg/spray |
| Market Status | Prescription |
| Company | Glaxosmithkline |
| 14 of 14 | |
|---|---|
| Drug Name | Flovent diskus 100 |
| Active Ingredient | Fluticasone propionate |
| Dosage Form | Powder |
| Route | Inhalation |
| Strength | 0.1mg/inh |
| Market Status | Prescription |
| Company | Glaxo Grp |
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
FDA Label
Treatment of asthma
Systemically, fluticasone propionate activates glucocorticoid receptors, and inhibits lung eosinophilia in rats. Fluticasone propionate as a topical formulation is also associated with vasoconstriction in the skin.
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Absorption
Intranasal bioavailability of fluticasone propionate is <2%, and oral bioavailability is <1%. Intranasal exposure results in the majority of the dose being swallowed. Topical absorption of fluticasone propionate is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%.
Route of Elimination
Fluticasone propionate is mainly eliminated in the feces with <5% eliminated in the urine.
Volume of Distribution
The volume of distribution of intravenous fluticasone propionate is 4.2L/kg. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration.
Clearance
1093mL/min for fluticasone propionate. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration.
Fluticasone propionate is cleared from hepatic metabolism by cytochrome P450 3A4. Fluticasone propionate is hydrolysed at the FIVE-S-fluoromethyl carbothioate group, forming an inactive metabolite.
7.8 hours for intravenous fluticasone propionate. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation.
Fluticasone propionate works through an unknown mechanism to affect the action of various cell types and mediators of inflammation. Fluticasone propionate activates glucocorticoid receptors and inhibits lung eosinophilia in rats.
API SUPPLIERS
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
Certificate Number : R1-CEP 2018-040 - Rev 00
Issue Date : 2023-05-03
Type : Chemical
Substance Number : 1750
Status : Valid
Registration Number : 303MF10172
Registrant's Address : 15 rue Traversie(')re 75012 Paris France
Initial Date of Registration : 2021-12-09
Latest Date of Registration : --
Registrant Name : Korea Mundipharma Co., Ltd.
Registration Date : 2024-05-31
Registration Number : 20240531-209-J-1652
Manufacturer Name : Euroapi France
Manufacturer Address : 4 Lieu Dit La Paterie, Vertolaye, 63480, France
Coral's API range includes Corticosteroids, Antihistamines. Hormones and Antineoplastics.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-05-11
Pay. Date : 2018-04-10
DMF Number : 21879
Submission : 2008-08-12
Status : Active
Type : II
Certificate Number : R1-CEP 2005-055 - Rev 03
Issue Date : 2020-09-25
Type : Chemical
Substance Number : 1750
Status : Valid
Date of Issue : 2022-09-16
Valid Till : 2025-07-05
Written Confirmation Number : WC-0009
Address of the Firm :
NDC Package Code : 49076-5501
Start Marketing Date : 2018-10-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.
Certificate Number : CEP 2020-078 - Rev 02
Issue Date : 2023-12-11
Type : Chemical
Substance Number : 1750
Status : Valid
Date of Issue : 2022-06-13
Valid Till : 2025-07-02
Written Confirmation Number : WC-0155
Address of the Firm :
NDC Package Code : 66412-0679
Start Marketing Date : 2023-09-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Axplora- The partner of choice for complex APIs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-11-02
Pay. Date : 2018-10-31
DMF Number : 20463
Submission : 2007-04-24
Status : Active
Type : II
Certificate Number : CEP 2008-117 - Rev 02
Issue Date : 2024-05-23
Type : Chemical
Substance Number : 1750
Status : Valid
NDC Package Code : 46439-8729
Start Marketing Date : 2007-04-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Certificate Number : R0-CEP 2013-158 - Rev 02
Issue Date : 2016-07-08
Type : Chemical
Substance Number : 1750
Status : Expired
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-05-23
Pay. Date : 2014-05-05
DMF Number : 15456
Submission : 2001-05-24
Status : Active
Type : II
Certificate Number : CEP 2007-192 - Rev 09
Issue Date : 2024-11-26
Type : Chemical
Substance Number : 1750
Status : Valid
Registration Number : 218MF10834
Registrant's Address : Offer Park, Building C, 4th floor, 94 Shlomo Shmeltzer Road, POB 3158, Petah Tikva 4970602, Israel
Initial Date of Registration : 2006-10-20
Latest Date of Registration : --
NDC Package Code : 58175-0361
Start Marketing Date : 2000-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : Canada DMF |
Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
NDC Package Code : 22552-0043
Start Marketing Date : 2015-01-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Jai Radhe Sales is your partner for all your sourcing needs.
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-06-02
Pay. Date : 2013-03-11
DMF Number : 22980
Submission : 2009-07-22
Status : Active
Type : II
Certificate Number : R1-CEP 2007-262 - Rev 03
Issue Date : 2022-10-14
Type : Chemical
Substance Number : 1750
Status : Valid
Date of Issue : 2023-01-06
Valid Till : 2025-07-29
Written Confirmation Number : WC-0099
Address of the Firm :
NDC Package Code : 15308-0200
Start Marketing Date : 2005-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Coral's API range includes Corticosteroids, Antihistamines. Hormones and Antineoplastics.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36315
Submission : 2021-11-18
Status : Active
Type : II
Coral's API range includes Corticosteroids, Antihistamines. Hormones and Antineoplastics.
GDUFA
DMF Review : Complete
Rev. Date : 2018-05-11
Pay. Date : 2018-04-10
DMF Number : 21879
Submission : 2008-08-12
Status : Active
Type : II
Axplora- The partner of choice for complex APIs.
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-02
Pay. Date : 2018-10-31
DMF Number : 20463
Submission : 2007-04-24
Status : Active
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-23
Pay. Date : 2014-05-05
DMF Number : 15456
Submission : 2001-05-24
Status : Active
Type : II
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
GDUFA
DMF Review : Complete
Rev. Date : 2014-06-02
Pay. Date : 2013-03-11
DMF Number : 22980
Submission : 2009-07-22
Status : Active
Type : II
TAPI offers customized CDMO Solutions for API development and manufacturing services.
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-30
Pay. Date : 2012-11-08
DMF Number : 15745
Submission : 2001-11-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-25
Pay. Date : 2014-08-14
DMF Number : 15774
Submission : 2001-12-19
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-15
Pay. Date : 2012-12-14
DMF Number : 16334
Submission : 2002-12-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15686
Submission : 2001-10-19
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-31
Pay. Date : 2014-10-20
DMF Number : 16423
Submission : 2003-02-12
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - OINTMENT;TOPICAL - 0.005% **Federal ...DOSAGE - OINTMENT;TOPICAL - 0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19957
DOSAGE - SPRAY, METERED;NASAL - 0.05MG/SPRAY ...DOSAGE - SPRAY, METERED;NASAL - 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20121
DOSAGE - SPRAY, METERED;NASAL - 0.137MG/SPRAY...DOSAGE - SPRAY, METERED;NASAL - 0.137MG/SPRAY;0.05MG/SPRAY
USFDA APPLICATION NUMBER - 202236
DOSAGE - SPRAY, METERED;NASAL - 0.05MG/SPRAY
USFDA APPLICATION NUMBER - 205434
DOSAGE - POWDER;INHALATION - 0.05MG/INH
USFDA APPLICATION NUMBER - 20833
DOSAGE - POWDER;INHALATION - 0.1MG/INH
USFDA APPLICATION NUMBER - 20833
DOSAGE - POWDER;INHALATION - 0.25MG/INH
USFDA APPLICATION NUMBER - 20833
DOSAGE - POWDER;INHALATION - 0.03MG/INH
USFDA APPLICATION NUMBER - 208798
DOSAGE - POWDER;INHALATION - 0.055MG/INH
USFDA APPLICATION NUMBER - 208798
DOSAGE - POWDER;INHALATION - 0.113MG/INH
USFDA APPLICATION NUMBER - 208798
DOSAGE - POWDER;INHALATION - 0.232MG/INH
USFDA APPLICATION NUMBER - 208798
DOSAGE - POWDER;INHALATION - 0.055MG/INH;EQ 0...DOSAGE - POWDER;INHALATION - 0.055MG/INH;EQ 0.014MG BASE/INH
USFDA APPLICATION NUMBER - 208799
DOSAGE - POWDER;INHALATION - 0.113MG/INH;EQ 0...DOSAGE - POWDER;INHALATION - 0.113MG/INH;EQ 0.014MG BASE/INH
USFDA APPLICATION NUMBER - 208799
DOSAGE - POWDER;INHALATION - 0.232MG/INH;EQ 0...DOSAGE - POWDER;INHALATION - 0.232MG/INH;EQ 0.014MG BASE/INH
USFDA APPLICATION NUMBER - 208799
DOSAGE - POWDER;INHALATION - 0.1MG/INH;EQ 0.0...DOSAGE - POWDER;INHALATION - 0.1MG/INH;EQ 0.05MG BASE/INH
USFDA APPLICATION NUMBER - 21077
DOSAGE - POWDER;INHALATION - 0.25MG/INH;EQ 0....DOSAGE - POWDER;INHALATION - 0.25MG/INH;EQ 0.05MG BASE/INH
USFDA APPLICATION NUMBER - 21077
DOSAGE - POWDER;INHALATION - 0.5MG/INH;EQ 0.0...DOSAGE - POWDER;INHALATION - 0.5MG/INH;EQ 0.05MG BASE/INH
USFDA APPLICATION NUMBER - 21077
DOSAGE - LOTION;TOPICAL - 0.05% **Federal Reg...DOSAGE - LOTION;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 21152
DOSAGE - AEROSOL, METERED;INHALATION - 0.045M...DOSAGE - AEROSOL, METERED;INHALATION - 0.045MG/INH;EQ 0.021MG BASE/INH
USFDA APPLICATION NUMBER - 21254
DOSAGE - AEROSOL, METERED;INHALATION - 0.115M...DOSAGE - AEROSOL, METERED;INHALATION - 0.115MG/INH;EQ 0.021MG BASE/INH
USFDA APPLICATION NUMBER - 21254
DOSAGE - AEROSOL, METERED;INHALATION - 0.23MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.23MG/INH;EQ 0.021MG BASE/INH
USFDA APPLICATION NUMBER - 21254
DOSAGE - AEROSOL, METERED;INHALATION - 0.044M...DOSAGE - AEROSOL, METERED;INHALATION - 0.044MG/INH
USFDA APPLICATION NUMBER - 21433
DOSAGE - AEROSOL, METERED;INHALATION - 0.11MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.11MG/INH
USFDA APPLICATION NUMBER - 21433
DOSAGE - AEROSOL, METERED;INHALATION - 0.22MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.22MG/INH
USFDA APPLICATION NUMBER - 21433
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Solubilizers
Thickeners and Stabilizers
Topical
Disintegrants & Superdisintegrants
Co-Processed Excipients
Parenteral
Granulation
Emulsifying Agents
Controlled & Modified Release
Film Formers & Plasticizers
Coating Systems & Additives
Surfactant & Foaming Agents
Rheology Modifiers
Taste Masking
Chewable & Orodispersible Aids
Lubricants & Glidants
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Flixotide Inhaler manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flixotide Inhaler, including repackagers and relabelers. The FDA regulates Flixotide Inhaler manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flixotide Inhaler API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Flixotide Inhaler manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Flixotide Inhaler supplier is an individual or a company that provides Flixotide Inhaler active pharmaceutical ingredient (API) or Flixotide Inhaler finished formulations upon request. The Flixotide Inhaler suppliers may include Flixotide Inhaler API manufacturers, exporters, distributors and traders.
click here to find a list of Flixotide Inhaler suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Flixotide Inhaler DMF (Drug Master File) is a document detailing the whole manufacturing process of Flixotide Inhaler active pharmaceutical ingredient (API) in detail. Different forms of Flixotide Inhaler DMFs exist exist since differing nations have different regulations, such as Flixotide Inhaler USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Flixotide Inhaler DMF submitted to regulatory agencies in the US is known as a USDMF. Flixotide Inhaler USDMF includes data on Flixotide Inhaler's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Flixotide Inhaler USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Flixotide Inhaler suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Flixotide Inhaler Drug Master File in Japan (Flixotide Inhaler JDMF) empowers Flixotide Inhaler API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Flixotide Inhaler JDMF during the approval evaluation for pharmaceutical products. At the time of Flixotide Inhaler JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Flixotide Inhaler suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Flixotide Inhaler Drug Master File in Korea (Flixotide Inhaler KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Flixotide Inhaler. The MFDS reviews the Flixotide Inhaler KDMF as part of the drug registration process and uses the information provided in the Flixotide Inhaler KDMF to evaluate the safety and efficacy of the drug.
After submitting a Flixotide Inhaler KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Flixotide Inhaler API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Flixotide Inhaler suppliers with KDMF on PharmaCompass.
A Flixotide Inhaler CEP of the European Pharmacopoeia monograph is often referred to as a Flixotide Inhaler Certificate of Suitability (COS). The purpose of a Flixotide Inhaler CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Flixotide Inhaler EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Flixotide Inhaler to their clients by showing that a Flixotide Inhaler CEP has been issued for it. The manufacturer submits a Flixotide Inhaler CEP (COS) as part of the market authorization procedure, and it takes on the role of a Flixotide Inhaler CEP holder for the record. Additionally, the data presented in the Flixotide Inhaler CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Flixotide Inhaler DMF.
A Flixotide Inhaler CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Flixotide Inhaler CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Flixotide Inhaler suppliers with CEP (COS) on PharmaCompass.
A Flixotide Inhaler written confirmation (Flixotide Inhaler WC) is an official document issued by a regulatory agency to a Flixotide Inhaler manufacturer, verifying that the manufacturing facility of a Flixotide Inhaler active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Flixotide Inhaler APIs or Flixotide Inhaler finished pharmaceutical products to another nation, regulatory agencies frequently require a Flixotide Inhaler WC (written confirmation) as part of the regulatory process.
click here to find a list of Flixotide Inhaler suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Flixotide Inhaler as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Flixotide Inhaler API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Flixotide Inhaler as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Flixotide Inhaler and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Flixotide Inhaler NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Flixotide Inhaler suppliers with NDC on PharmaCompass.
Flixotide Inhaler Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Flixotide Inhaler GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flixotide Inhaler GMP manufacturer or Flixotide Inhaler GMP API supplier for your needs.
A Flixotide Inhaler CoA (Certificate of Analysis) is a formal document that attests to Flixotide Inhaler's compliance with Flixotide Inhaler specifications and serves as a tool for batch-level quality control.
Flixotide Inhaler CoA mostly includes findings from lab analyses of a specific batch. For each Flixotide Inhaler CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Flixotide Inhaler may be tested according to a variety of international standards, such as European Pharmacopoeia (Flixotide Inhaler EP), Flixotide Inhaler JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flixotide Inhaler USP).
LOOKING FOR A SUPPLIER?
